Turkish
Biopharmaceuticals and
Vaccines Platform

Turkish
Biopharmaceuticals and
Vaccines Platform

Nef 09 B Blok Kat: 10 Sanayi Mah. Hümeyra Sok. No: 7 34415 Kağıthane / İstanbul Tel: +90 (212) 353 11 20

Turkish
Biopharmaceuticals and
Vaccines Platform

April 2022

Turkish
Biopharmaceuticals and
Vaccines Platform

The main activities of the Turkish Biopharmaceuticals and Vaccines Platform are as follows:

The Platform was established in 2016, with the participation of companies in the biotechnology field not limited to IEIS members. Its purpose is to contribute to the development of biopharmaceuticals field in our country.

As of January 2022, we expanded our scope of activities and included vaccines in our fields of activity.

The main activities of the Turkish Biopharmaceuticals Platform are as follows:

- Dealing with issues related to biopharmaceuticals and vaccines and developing position papers,
- Trying to establish an efective incentive scheme in this area,
- Creating a regulatory environment in line with needs,
- Developing close cooperation with public and academic institutions,
- Boosting health professionals' knowledge and awareness related to biopharmaceuticals,
- Collaborating with national and international NGO's,
- Organizing local and international biotechnological events.

Turkish Biopharmaceuticals and Vaccines Platform Catalogue, published in April 2022 by IKEV

Turkish Biopharmaceuticals and Vaccines Platform

MEMBERS

- Abdi İbrahim Pharmaceuticals
- Adeka Pharmaceuticals
- Ali Raif Pharmaceuticals
- Arven Pharmaceuticals
- Atabay Pharmaceuticals and Fine Chemicals
- Centurion Pharmaceuticals
- CinnaGen Pharmaceuticals
- Dem Pharmaceuticals
- Eczacıbaşı Pharmaceuticals Marketing
- Florabio
- Hasbiotech Pharmaceuticals
- Foundation of Research and Development in Pharmaceutical Industry of Turkey (IKEV)
- ILKO Pharmaceuticals
- Koçak Farma
- Liba Laboratories
- Gensenta Pharmaceuticals
- Nobel Pharmaceuticals
- Omega CRO
- Onko Koçsel Pharmaceuticals
- Pharmactive Pharmaceuticals
- Teva Pharmaceuticals
- TRPHARM Pharmaceuticals
- Turgut Pharmaceuticals
- Vem Pharmaceuticals



Company Name:
Abdi İbrahim Pharmaceuticals
Company Web:
www.abdiibrahim.com.tr/en

Turkish Biopharmaceuticals and Vaccines Platform

Abdi İbrahim, the Turkish pharmaceutical industry leader, was founded at a small pharmacy in 1912 in Istanbul, by pharmacist Abdi İbrahim Bey. Abdi İbrahim has the largest product portfolio in the sector, with nearly 250 brands and more than 450 products. Abdi İbrahim develops its own products in its R&D Centre besides establishing licensing agreements and presenting licensors's products.

With its powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of Turkey's pharmaceutical industry since 2002. Today, Abdi İbrahim, which operates in 14 countries outside Turkey, exports to more than 60 countries ranging from Canada to European Union member states, from North Africa to Asia, and is the largest employer in the Turkish pharmaceutical industry with 4.750 qualified employees. The company also leads with its marketing and sales team, which is the largest in the industry.

As well as its R&D Centre, Abdi İbrahim has a manufacturing facility for chemical products, Turkey's largest biotechnological manufacturing facility AbdiBio, a hormone production facility, a sterile ophthalmology and sterile inhalation products production facility, and a sterile injectable and oncology products production facility which will be operational in 2023 in Istanbul's Esenyurt production complex. Abdi İbrahim has also R&D centres and production facilities in Kazakhstan and Algeria.
A strong testament to Abdi İbrahim's endeavor to open a world-class biopharmaceutical production facility, AbdiBio commenced its operations in May 2018 in its Esenyurt Production Complex. Equipped with advanced technology, the purpose of this facility is to create a strong and wide-ranging biotech product portfolio and to heal more lives with these medicines. In AbdiBio built on a total indoor area of 13,000 m², in which is performed all production processes starting from the cell bank to the final product, and manufacture products for the treatment of cancer, diabetes, rheumatism, central nervous system, eye and blood diseases. The facility boasts an annual output capacity of 11 million vials, 9 million syringes and 22 million cartridges. Embodying the best technologies observed around the world and at its business partners, generating local know-how and ensuring product diversity so as to create long-term value through value-added and innovative products are the fundamental elements of AbdiBio's strategy.

As a corporate citizen working towards creating a better world and a better future, adhering to its mission in the sector and to the requirements of societal priorities, Abdi İbrahim focuses on sustainability in all its business processes. Approaching all of its actions from the standpoint of environmental, social and governance (ESG) criteria, Abdi İbrahim has made it possible to gauge the company's performance not only on the basis of positive financial results, but also from the perspective of its positive impact on the community and the environment.

Stepping forward in the area of maintaining sustainability as a part of its process of green transformation, Abdi İbrahim upholds the European Green Deal and the Sustainable Development Goals (SDGs) adopted by the United Nations, and also relies upon processes such as Corporate Prioritization Analysis and Organizational Life Cycle Analysis (O-LCA) to achieve improvements in all its business processes in the light of its many sustainability projects.

As from 2020, Abdi İbrahim became the first pharmaceuticals company in Turkey to use 100 percent renewable energy, with solar and wind energy plants that meet the energy needs of all its facilities and buildings. Making significant strides to reduce its carbon footprint, Abdi İbrahim's goal is to become a carbon neutral company by 2030.

Contact Person

Name Surname: Buket Koral Gönüllü
Position: Corporate Communications Manager
E-mail: buket.koral@abdiibrahim.com.tr

Name Surname: Elif Ülkü
Position: Business Development Manager
E-mail: elif.ulku@abdiibrahim.com.tr

Company Name:
Adeka Pharmaceuticals
Company Web:
www.adeka.com.tr

Adeka was founded in Samsun on December 6, 1956 as the first Turkish pharmaceutical company that manufactures in Anatolia. The production is being carried out in the facility which was modernized in Samsun in 1995, in the covered area of 4000 m^2 and the construction of the new facility is still on going in Samsun. Adeka represents world's leading pharmaceutical companies in Turkey. In addition to its own pharmaceuticals, it also manufactures their pharmaceuticals in its own facilities and markets them. With modern production techniques and technology, it has a production capacity of 65 million boxes per year in accordance with cGMP and GLP standards.

Contact Person

Name Surname: Deniz Arpacıoğlu
Position: Vice Chairman of the Board
Phone: +90 212 365 08 00
E-mail: deniz.arpacioglu@adeka.com.tr

Name Surname: Şule İmer
Position: Regulatory Affairs Director
Phone: +90 212 365 08 00
E-mail: sule.imer@adeka.com.tr

Name Surname: Aslı Acar
Position: Medical Department Manager
Phone: +90 212 365 08 00
E-mail: asli.acar@adeka.com.tr

Company Name:
Ali Raif Pharmaceuticals
Company Web:
www.aliraif.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Ali Raif Pharmaceuticals (ARIS), which was established under the name of Ali Raif ve Seriki in 1928, was reorganized to trade in Turkish pharmaceutical industry by Muzaffer Turhan as of 1963.

It has 210 different pharmaceutical forms that contribute in enhancing the quality of life thanks to their therapeutic fields such as cardiovascular, diabetics, gastrointestinal, analgesic, anti-inflammatory, anti-flu, antiviral, antihistaminic, central nervous system, transplantation products. It has been serving Turkish Pharmaceutical Industry for 59 years with its qualified pharmaceutical production and institutional stance and continues to cooperate with global companies.

Ali Raif Pharmaceuticals aims to always offer better service to its customers and partners with the mission of "Value added life". To facilitate product access to the countries it can reach both in our country and in the world, Ali Raif increases its human resources and production resources, also develops and supports them with continuous investments. Import, export production, domestic promotion and marketing activities are carried out with strong staff in Istanbul Ikitelli Production Facilities, Istanbul 4th Levent Head Office and totally 10 area offices in Turkey.

In 2010, in recognition of its social and environmental responsibilities, Ali Raif Pharmaceuticals has signed the United Nations Global Principles Agreement to support and defend its ten basic principles on human rights, labor standards, environmental management and anti-corruption.

Its R&D department, which has been conducting research and development activities for many years, continues to work as an R&D center approved by the Ministry of Science and Technology on 12 January 2017.

Ali Raif Pharmaceuticals, breaked ground for its New Production Facility in Ikitelli in 2021 which aims to quadruple its current production capacity, increase employment by 30 percent, and boost exports. Ali Raif Pharmaceuticals in the first 20 firms in the unit and value rank in the Turkish pharmaceutical market, has adopted the approach that always trusts ethical work and stakeholders as a standard since 59 years. Ali Raif Pharmaceuticals continues to be one of the leading players in the sector with its mission to add value to life and continues to build the future by expanding production volume within the new product portfolio and localization.

Contact Person

Name: Seda Turhan Bilen

Position: Corporate Communications Manager

Phone: +90 212 316 78 00

E-mail: seda@aliraif.com.tr

Company Name:
Arven Pharmaceuticals
Company Web:
www.arvenilac.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Toksöz Group began investments on development and production of biotechnological drugs in 2007. Arven Pharmaceuticals; a 100% Turkish capitalized pharmaceutical company, succeeded in developing, manufacturing and authorisating first "from cell to finished product" biosimilar in Turkish pharma industry. Moreover, Toksöz Group's investments on developing high technology products brought the success of development of the first Turkish patented dry powder inhaler "Arvohaler®" as a result of long lasting R&D activities, which is a very important milestone in Turkish Pharmaceutical Industry.

Arven Pharmaceuticals Manufacturing plant for high-tech products, which is established on a closed area of 28,000 m2 in the Kırklareli Organised Industrial Zone, one of Toksöz Group's main investments in this regard, started to operate in 2017. Reaching commercial production levels without compromising product quality is the most critical step of the development process, as well as an important mission Arven Pharmaceuticals has adopted for advancement in public health.
Arven Pharmaceuticals aim to produce biosimilars of expensive biological medicines in quality standards that will satisfy authorities, and to offer these products for the benefit of public health. Employing promising youth who have completed degree programs in relevant areas (Molecular Biology and Genetics, Biology, Bioengineering, etc.) to reach this goal would also prove a valuable asset for our nation.

Arven Pharmaceuticals follows guidelines published by the World Health Organization, European Medicines Agency and USA Food and Drug Administration during the biosimilar development process. The "Every Product is a Process" approach and the importance of quality during this process are the pillars of Arven Pharmaceuticals' operations. Arven Pharmaceuticals conducts the majority of structural and functional analyses recommended in international guidelines with its current infrastructure and experts in relevant fields.

Arven Pharmaceuticals continues its efforts towards improving public health with its qualified researchers and personnel, who have experience in biosimilar product development and hold advanced degrees, and its biosimilar product development infrastructure, which continues to grow each day.

Contact Person
Name Surname: Zafer Toksöz
Position: Chairman
E-mail: zafertoksoz@toksozgrup.com.tr

Name Surname: Görkem Sert
Position: Facility Director
E-mail: gorkemsert@arvenilac.com.tr

Name Surname: Burcu Mutlugeldi
Position: Regulatory Affairs & Clinical Research Executive
E-mail: burcumutlugeldi@arvenilac.com.tr

Company Name:
Atabay Pharmaceuticals and Fine Chemicals
Company Web:
www.atabay.com

Turkish Biopharmaceuticals and Vaccines Platform

Atabay was founded in Istanbul by Mr. Ö. Kemalettin Atabay, Pharmacist, in 1939, prior to the outbreak of the Second World War. The company had emerged as a trading business, importing and marketing pharmaceutical products. In the 1940's, this medium sized commercial operation developed into the production of sulfonamide tablets, which were in great demand at the time, thus paving the way to the pharmaceutical industry in Turkey. By 1954, Atabay Pharmaceutical Products Inc. had evolved into a well-equipped modern plant. The initial product line expanded to include analgesics, apart from sulfonamides. Atabay's rapid growth, in due time, necessitated a larger plant. Consequently, in 1967, this facility was established at its present site in Acıbadem, Istanbul.

After successful years of performance in pharmaceuticals, Mr. Bülent Atabay, Chemical Engineer and President, prompted back – integration and entered in to the manufacture of fine chemicals. In 1970, the site of Atabay Pharmaceutical Fine Chemicals Inc was chosen at Gebze, near Istanbul. Five years later, in addition to the premises for the pharmaceutical fine chemicals, extensive facilities were set up in a separate area in Gebze to produce chemicals for the agricultural, public health and veterinary fields.

In 2015, Atabay started a biotechnology project with the support of TÜBİTAK KAMAG 1007, on the development and production of a bioengineered monoclonal antibody fragment. Which is currently at Clinical Trial Phase-3 stage. Built a new cGMP facility dedicated to microbial manufacturing and development, received the GMP certification from the MoH of Turkey in 2021. The very same year extended the facility for DNA Vaccine development and received also the vaccine production GMP. In the meantime, designed a microbial cells by recombinant DNA technology for production of the monoclonal antibody and received a GMP certificate for the Cell Bank. Cell line development, process development and scale-up as well as detailed analytics are carried out within the group. Atabay will continue to develop production of enzymes, antibody fragments, other biosimilars and vaccines using microbial fermentation.

Today, the Atabay enterprises, managed by a progressive and technically trained executive staff, is fully active in producing quality products for human and animal health. Marketing and promotion of the products are accomplished by a competitive sales network with distributors in the domestic as well as international arenas.

Contact Person

Name Surname: Doğan Taşkent

Position: Head of R&D and Innovation

Phone: +90 216 326 65 33

E-mail: dogan.taskent@atabay.com

Company Name:
Centurion Pharmaceuticals
Company Web:
www.centurion.com.tr

Believing that every patient deserves modern treatment and high quality of life, Centurion started its journey in 1979 in cooperation with Turkey's and the world's leading institutions; offering biologicals, orphan products, niche hospital generics and vaccines which are placed in today's modern treatment alternatives.

Centurion Pharmaceuticals Manufacturing and R&D Facility, with an area of 26.000 m2, is located in Ankara province and has the capability of developing biological products and niche hospital products. Operating under high quality standards, Centurion Manufacturing facilities has received Turkish GMP certificate on 2018 with the capability of fill and finish of biological products. Centurion is ready to expand its operations to EU markets after receiving the EU GMP certificate on January 2022.

The capacity of its manufacturing facility as a single shift is; 10 M vials, 5 M syringes and 3 M cartridges annually. In the field of biosimilars, orphan drugs and vaccine products, the company is collaborating with leading companies from all over the world and developing common projects in innovative therapeutic areas. Export oriented activities has started beginning of 2017 with the aim of expanding its sales to other markets mainly; MENA, CIS, GCC, LATAM and EU markets.

The product portfolio includes biosimilar products (TNF alpha blockers, EPO, interferons), niche hospital products, plasma products (Human Albumin, IVIG), niche hospital generics and orphan drugs. In addition, Centurion has the experience in importing Pharmaceuticals under name patient system.

Adopting humanity, nature and respect as its core values Centurion Pharmaceuticals will continue to focus on higher goals in the coming years, with the responsibility of being a flexible, creative, competitive and business-focused company philosophy and being one of the leading companies in its field.

Contact Person
Name Surname: Tansun Uzunoğlu
Position: Business Development Manager
Phone: +90 212 275 07 08
E-mail: tansunuzunoglu@centurion.com.tr

Company Name:
CinnaGen Pharmaceuticals
Company Web:
www.cinnagenilac.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Established in 2016, CinnaGen Ilac, is a local biopharmaceutical company headquartered in Istanbul, Turkey for manufacturing and selling biosimilar products across Europe and Turkey. The factory in Çerkezköy Organized Industrial Zone, which has GMP certificate for the production of biotechnological products starting from the Master Cell Bank and for the production of adenovirus vector-based vaccine, has a closed area of 7112 m^2 and a clean area of 1750 m^2. CinnaGen Ilac has a wide range spectrum product portfolio of recombinant protein and monoclonal antibody drugs, used in the treatment of cancer, central nervous system diseases, rheumatoid arthritis, hematological diseases, rare diseases, and serious autoimmune diseases.

Contact Person

Name Surname: Ferhat Farşi
Position: CEO
Phone: +90 216 504 77 27
Email: ferhat.farsi@cinnagenilac.com.tr

Name Surname: Esin Altınordulu
Position: Regulatory Affairs & Market Access Director
Phone: +90 216 504 77 27
Email: esin.altinordulu@cinnagenilac.com.tr

Company Name:
Dem Pharmaceuticals
Company Web:
www.demilac.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Based on values such as honesty, respect and trust, committed on its vision, mission and values, and being the icon of quality and trust within the pharmaceutical sector, Dem Pharmaceuticals has been established by a family devoted themselves to Turkish pharmaceutical industry since 1970.
Dem Pharmaceuticals continues to give their services to the Turkish Medicine since 1992 finding effective and fast results, improving its quality and increasing the variety of its services. Dem Pharmaceuticals, is incorporated in the Turkish pharmaceutical industry and sells imported and licensed drugs and medical preparations.

The product portfolio of Dem Pharmaceuticals includes blood and blood derivatives, anesthetic agents, plasma expanders, antibiotics, reference biotechnological products and biosimilars procured from the leading manufacturers of the world and licensed pharmeceuticals for human consumption manufactured in modern plants of Turkey. Dem Pharmaceuticals which is highly focused on new product research and invests in this area, holds about 100 license files for conventional pharmaceuticals, blood and blood derivatives. The company also holds import rights for some medical preparations with CE certificate besides the products for which it has licenses for export, manufacture and sub-manufacture.

In addition to those activities, Dem Pharmaceuticals has been developing its own biosimilar, nanosimilar and peptide derivative pharmaceuticals in its own R&D Labarotories. For manufacturing of the own-developed products and servicing as contract manufacturer; Dem Pharmaceuticals has just constructed its own high-tech biotechnological sterile manufacturing facility. The total closed area of this facility is 14756 m^2 and equipped with both vial, ampoule PFS filling lines and bioprocess equipments including bioreactors and downstream equipments.

Dem Pharmaceuticals continues to conduct researches worldwide to conclude new product agreements with licensors and to expand its portfolio in addition to products it markets and for which licensing works continue. Dem Pharmaceuticals takes firm steps forward with the support of its dynamic, creative and qualified staff who believe in team spirit with high individual motivation and are open to innovations and developments.

Contact Person
Name Surname: Esra Üstünyağız
Position: Scientific Department Director
Phone: +90 216 428 40 29
E-mail: esra@demilac.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Company Name:

Eczacıbaşı Pharmaceuticals Marketing

Company Web:

www.eczacibasi.com.tr

EİP Eczacıbaşı İlaç Pazarlama A.Ş. carries out the marketing, promotion, sales and distribution of imported and contract manufactured pharmaceuticals for mass and niche markets and health-based personal care products. Its growing portfolio currently comprises products licensed by Abdi İbrahim, Alfa-Sigma, Almirall, Arnet, Aspen, Biogaia, Chugai, Galderma, Haver, Juvise Pharmaceuticals, Novartis, Pharmamar, Procter&Gamble, Sanofi, Synthon, Tillotts Pharma, as well as its own brand of nutritional supplements. Additionally EİP Eczacıbaşı İlaç Pazarlama A.Ş. aims to find new global partnerships for therapeutical areas with unmet medical needs. EİP Eczacıbaşı İlaç Pazarlama A.Ş. has mainly two business units including Rx products and consumer healthcare working with regional representatives around the country. Over 20 district managers and some 200 sales representatives visit more than 25,000 doctors and 7,000 pharmacies on a regular basis. All visits are processed daily and monitored by the sales force automation system.

Contact Person

Name Surname: Orkun Erkuş

Position: Government Relations & Access Director

Phone: +90 212 350 80 00

E-mail: orkun.erkus@eczacibasi.com.tr



Company Name:
Florabio
Company Web:
www.florabio.com.tr

Florabio is a life science company with proprietary technology, know-how and experience in manufacturing therapeutic proteins. Florabio has developed the platform technologies for vaccine and recombinant protein production in the shortest time with the most economic measures. We provide our clients with production cells, culture media and our service to optimize protein glycosylation.

Florabio is one of the most experienced "Media development" and "Media optimization" company in today's marketplace. Dr. Aziz Cayli, founder of Florabio has developed more than 60 cell lines in his previous company called Cellca and the media he developed, "ActiPRO" is still the most sold media in the market.

Florabio has 23 different chemically defined cell culture medias in the market which are proven to be one of the best also in large scale manufacturing. Our media systems are used for commercial production of several Covid-19 vaccines including the first Covid-19 vaccine worldwide and many more.

Contact Person
Name Surname: Cem Erdem
Position: CEO
Phone: +90 532 374 04 70
E-mail: cerdem@florabio.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Company Name:
Foundation of Research and Development in Pharmaceutical Industry of Turkey (IKEV)
Company Web:
www.ikev.org

IKEV, established under the guidance of Pharmaceutical Manufacturers Association of Turkey (IEIS) in 1998, aims to perform research on improvement of pharmaceutical and chemical industries and follow up both scientific and technological developments.

IKEV makes effort to improve and educate the human resource of these sectors, provide a strong connection between the universities and the industry as well as to participate in determination of health policies by following up the scientific and current affairs

IKEV is one of the first organisations voicing that our country should make progress in the biotechnology field and perform necessary activities. It also organised various national and international events to improve the awareness in this regard. Currently, the Foundation keeps working on its activities accordingly.

Contact Person

Name Surname: Ferda Fındık Yakar
Phone: +90 212 353 11 20
E-mail: ferda.findik@ieis.org.tr

Name Surname: Burçin Karacabey
Phone: +90 212 353 11 20
E-mail: burcin.bademci@ieis.org.tr

Company Name:
ILKO Pharmaceuticals
Company Web:
www.ilkogen.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

ILKO Pharmaceuticals; With all its production and R&D investments, by using the advanced technologies needed by modern medicine, by offering "innovative" products that increase the quality of life of people and save lives; aims to be a leading company in global competition.
ILKO Pharmaceuticals has a wide product portfolio covering all major treatment areas, especially cardiology, central nervous system, rare diseases and acute products. It also operates in the fields of biotechnology and consumer health (with the Wellcare brand).

ILKO Pharmaceuticals Production Facilities,is the largest pharmaceutical production investment in Anatolia, started its operations in 2012. Production Facilities with the infrastructure to reach 120 million boxes; It has EU GMP, ISO 13485, ISO 45001, ISO 14001, ISO 27001, BS 10012, TSE Covid-19 Safe Production Place and Zero Waste certificates. ILKO Pharmaceuticals Production Facilities was established in 2013 by the T.C. It has been selected as 'Turkey's Cleanest Industrial Facility' by the Ministry of Environment and Urbanization.

ILKO Pharmaceuticals is focused on advanced technology and has the first and only production technologies in Turkey. 'Delayed-release Core-in Tablet Technology' (Chronopharmaceutical Product) and MUPS (Multiple Unit Pellet System/Multiple Unit Pellet System-Micropellet Technology) are only available at ILKO Pharmaceuticals.

ILKO Pharmaceuticals has a strong R&D structure and has two separate R&D Centers. Development of advanced technology and value-added products as well as small molecule generic products at the ILKO Argem R&D Center with a closed area of 2600 m^2 in Hacettepe Technopark Work is also in progress.
ILKO Argem Biotechnology Center, which was established in 2014 and is Turkey's first biotechnology R&D Center, continues its activities to develop biotechnological drugs by using recombinant DNA technology as a tool. At the center, which aims to develop biotechnological products for cancer and cancer-related diseases in the first stage, R&D and clinical studies on biosuperior, biosimilar and new generation biotechnological products are still being carried out.

ILKO Pharmaceuticals is one of the 10 pharmaceutical companies that spend the most on R&D in Turkey.
ILKOGEN is Turkey's international joint investment in biotech pharmaceutical R&D, biosimilar and biosuperior product development and marketing. ILKOGEN started its operations in 2013 as a result of the combination of ILKO Pharmaceuticals and the R&D expertise of South Korean biotechnology company Genexine in the field of biotechnology. ILKOGEN works to develop new generation biotechnology (biosuperior) and biosimilar drugs. The Phase II clinical trial of GX-G3, the first original biotechnological drug of ILKO to be used in the treatment of chemotherapy-induced neutropenia, has been successfully completed. It is currently successfully continuing clinical studies of the best-in-class, long-acting, third generation G-CSF developed with Genexine's patented hyFc technology. In this context, it is planned to introduce the first İLKOGEN branded product to the market in the coming years.

ILKO Pharmaceuticals; CIS carries out export activities in more than 25 countries in the Middle East, Balkans, Far East, Africa and Latin America regions and licensing activities in more than 40 countries.
ILKO Pharmaceuticals; In addition to its export activities, it is signing strategic cooperation with international companies within the scope of contracted production activities (CDMO / CMO).

Contact Person
Name Surname: Deniz Karaca Uygur
Position: Business Development Manager
Phone: 0 216 564 80 00
E-mail: dkuygur@ilko.com.tr

Company Name:
Koçak Farma

Company Web:
www.kocakfarma.com

Turkish Biopharmaceuticals and Vaccines Platform

Koçak Farma was founded in 1971. The company manufactures Conventional Medicine, Biotechnological/Biological Medicine, I.V. Solutions and Active Pharmaceutical Ingredients (API). Koçak Farma Production facilities in Çerkezköy Organized Industrial Region is established on 140.000 m^2 area and has 100.000 m^2 indoor area with 500 million unit/year production capacity. The I.V. Solution Production facilities in İstanbul/Ayazağa is established on 50.000 m^2 area and has 150 million unit/year production capacity Koçak Farma Group has around 2000 employees.

Koçak Farma is an " R&D Center" approved by Ministery of Science, Industry and Commerce. 100 specialists and scientists are doing research in the center.

Koçak Farma facilities consist of dedicated premised which are approved by EU authorities and have EU GMP certificate:

- Conventional Medicine Production Facilities
- Oncology Medicine Production Facilities
- Hormone Medicine Production Facilities
- Carbapenem Medicine Production Facilities
- Penicilline Medicine Production Facilities
- Biotechnological/Biological Products Production Facilities
- API Production Facilities

Koçak Farma has the capability of manufacturing all pharmaceutical forms in these dedicated areas. Koçak Farma has launched the first Biosimilar product in EU and Turkey , "Enoxaparin Sodium" in Prefilled Syringe form Turkey.

Koçak Farma has launched the first locally manufactured Insulin with Insulin Glargine API, "Glarin 100 U/ml Solution for Injection in Pen for SC Use" Koçak Farma will manufacture Insulin Analogues, Monoclonal Antibodies (mAbs), bacterial, viral and recombinant vaccines in its Biotechnological/Biological facilities in Çerkezköy Organized Region.

Koçak Farma is a leading company in the world in Oncology area with its broad product portfolio. Our company is manufacturing one of every 2 units of Oncology products used in Turkey Koçak Farma is exporting its products to more than 50 countires in 5 continents, particularly to EU countries including Germany, France, Italy, Spain etc. , from its facilities with EU GMP approval. Our vision is ; to manufacture high value added products by leading the structural transfromation of Turkish Pharmaceutical Industry, to contribute the conversion of the effect of foreign trade of the sector in economical growth from negative to positive with export, to support the target of being a regional R&D and Pharmaceutical Products Manufacturing Center in the frame of vision 2023 strategical plan of the country.

Contact Person

Name Surname: Cem Koçak

Position: Deputy General Manager

Phone: +90 212 410 39 50

E-mail: ckocak@kocakfarma.com

Company Name:
Liba Laboratories
Company Web:
www.liba.com.tr

Liba Laboratories was founded in 1945 by Lale and Necip Barlas in Istanbul. As one of the first pharmaceuticals companies of the Republic of Turkey, Liba's top priority has been contributing to public health and well-being. Liba has also prioritized and supported the development and progress of the Turkish pharmaceuticals industry for 77 years, and will continue to do so.

Its business consists of locally produced Liba-branded products and imported products that it distribute. Its net sales in 2017 were 14.3 m units and 30 m Euro. Liba is proud of its yearly growth rates, %31 in units, well above the market's growth rate. Its strategy is to support this growth through new products in development as well as new international cooperations.

Liba's main focus is ophthalmology and it is also active in the fields of psychiatry, neurology, dermatology and analgesics.

Liba's vision is to continue its work through the selection of innovative products in highly specific areas for the presentation to the Turkish healthcare sector under purely ethical standards.

Contact Person
Name Surname: Lale Barlas
Position: Business Development Director
Phone: +90 532 686 19 91
E-mail: lale.barlas@liba.com.tr

Company Name:
Nobel Pharmaceuticals
Company Web:
www.nobel.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Nobel Pharmaceuticals is a leading Turkish pharmaceutical company, headquartered in Istanbul, engaged in the research and development, manufacture, marketing and distribution of pharmaceutical products. With its twenty organizations outside of Turkey and EU-GMP certified manufacturing facilities, Nobel, is a strong and well-respected player in the domestic and international markets, and a gateway to Southeastern Europe and CIS countries.

Nobel as a multinational biopharmaceutical company with a strong emphasis on innovation, foresaw the future and focused on new molecule development as an area of strategic importance 15 years ago and launched investments in biotechnology area.
When it comes to biotechnology, Nobel has also taken the leadership in its territories. In 2009, Nobel successfully completed the registration of Epobel, the first bio-similar Eritropoetin in Turkey. Since its registration, the Epobel's market share has reached 25% among all the Short Acting Erythropoietin products in Turkey.

In 2014, Nobel was the first company who was deemed worthy of the largest Governmental Grant for the First National Biopharmaceutical (Biosimilar mAbs) Development & Production Project.
In 2017, it was also honored as the first domestic company to receive government support in the development of original biotechnological drugs.

In 2020, we also were being awarded for 3 more molecules development grants.

Today we have full scale of biotechnological product development activities.

- Our mammalian cell line process development lab with USP, DSP and BADL departments has been active since 2019 and capable of full development of 4 molecules every year. (Currently working on 4 molecules)
- Our 2x1000L single use manufacturing facility which is the biggest mammalian cell line facility in the region, is fully qualified and and waiting for GMP audit by Turkish MoH.
- Our QC lab is fully equipped to release biopharmaceutical products according to not only for Turkish MoH but also other authorities as well.

Our proudest moment came in 2020 when we were called by Turkish government to be a part of National Covid-19 vaccine development project. With our experienced and dedicated team of 90 people, Nobel was able to develop, manufacture and run a Phase I and Phase II clinical studies within only one year. Virus Like Particle based our vaccine is currently under Phase IIb study.

All biotech investments on biosimilars (mAbs, glycoproteins, enzymes) and original (bio) molecule development are the driving forces of Nobel, and with leading such projects Nobel plans to become the flagship of the biotechnological industry in Turkey

Contact Person

Name Surname: Hasan Zeytin MD., Ph.D.

Position: Biotechnological Project and New Product Assessment Director

Phone: +90 216 633 62 72

E-mail: hasan.zeytin@nobel.com.tr

Company Name:
Omega CRO
Company Web:
www.omega-cro.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Omega CRO, founded in March 1997, is the first and still the biggest CRO in Turkey with its full range of services, is an independent research organization specialized in both clinical trials and observational trials, as well as the epidemiological studies. In addition, Omega CRO is actively working for the vaccine trials since the beginning of the COVID-19 pandemic. We conducted the Phase III clinical trials of CoronaVac® and TURKOVAC vaccines in Turkey. The results of these trials were used to get Emergency Use Authorization for these vaccines in Turkey.

Our senior staff has much experience on not only planning, conducting and monitoring clinical and epidemiological studies, but also data management, data analysis and presentation of data. We have over 120 full time staff with below 5% of staff turnover rate. Our staff has extensive experience in clinical research from both industry and investigator perspectives. We had managed clinical trials in many major therapeutic areas, and with this experience, Omega CRO offers particular expertise in the management of clinical trials in infectious diseases, neurology, psychiatry, haematology/oncology, cardiovascular diseases, endocrinology, urology, chest diseases, ENT and also others.

Additionally , Omega CRO, has it own laboratories (Genetic Diseases Diagnostic Center, microbiology and biochemistry and R&D laboratory), licensed home care services for clinical trials, chronic diseases and educational nursing and investigational medicinal product warehouse.

Contact Person
Name Surname: Berna Hatunoğlu
Position: Corporate Relations Coordinator
Phone: +90 312 426 77 42
E-mail: bernah@omega-cro.com.tr

Company Name:
Pharmactive Pharmaceuticals
Company Web:
www.pharmactive.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Pharmactive was established in 2010 with the understanding of human wellbeing. The foundations of Pharmactive's production facility in Çerkezköy were laid on 14 February 2011, with the mission of "to develop and produce pharmaceuticals at high quality standards and to be active for human health by making pharmaceuticals accessible to everyone".

Pharmactive production base, holding the European GMP certificate given by Germany Federal Institute for Drugs and Medical Devices (BfArM), one of the most respected authorities in Europe, is one of the few production facilities with this certificate in our country.

In 2016, Pharmactive partnered with Korean Biotechnology firm Polus and has exclusive rights for 34 countries for biotechnological products. First production facility has been built in Korea with further expansion plans.

Pharmactive, which entered the Russian market in 2019 by obtaining the Russian GMP certificate from the Russian Authority, received the Canadian GMP certificate in 2021 as a result of the inspections made by the Canadian Ministry of Health. Pharmactive's production base is one of the well-known pharmaceutical production facilities not only in Turkey but also throughout the world.

Pharmactive's R&D center "PharmAR-GE", established on an area of 3200 m^2 in its modern facility, which has a production capacity of 330 million boxes of drugs in solid, semi-solid and liquid lines, is one of the few pharmaceutical R&D centers approved by the Ministry of Industry and Technology. Pharmactive, offer high quality products for the benefit of Healthcare Providers and Patients in different therapeutic areas through its experienced team. It is the business partner of multinational companies in Turkey with regard to its flexible and high production capacity.

By this means, Pharmactive has also made great contributions to localization policies in Turkey.

Taking firm steps towards becoming one of Turkey's largest generic pharmaceutical companies, with the strength it draws from the values of "Reliability", "Being Usefull", "Value For Human, Merit", "Global Competition" determined at its establishment; Pharmactive continues to work for health and produce for the world, with pharmaceuticals at high quality standards and at affordable costs.

Contact Person

Name Surname: Hakan Gürel

Position: Business Development & Export Director

Phone: +90 212 604 55 00 - 3071

E-mail: hakan.gurel@pharmactive.com

Company Name:
Teva Pharmaceuticals
Company Web:
www.teva.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

We are proud that since Teva's establishment in 1901, healthcare providers together with patients and caregivers have been using our accessible generic and innovative products. Today, our portfolio of around 3,500 products is among the largest of any pharmaceutical company in the world. Nearly 200 million people benefit from one of Teva's quality medicines every day, where there are more than 60 manufacturing sites around the world. We invest in research and development of generic medicines and biopharmaceuticals, carrying on the legacy of more than a century of finding new ways to help patients improve their lives. This defines our values as a company and characterizes how we do business and approach medicine.

40.000 Teva employees around the Globe start the day with one mission and that is; to be a global leader in generics and biopharmaceuticals, improving the lives of patients. It gives meaning to everything we do. It is about us, the people of Teva, applying our dedication, capabilities, and skills, as well as our passion and human touch, to make better days and better health for millions of people worldwide. Our mission and values guide us to ensure that you - our patients, our customers, our colleagues, and our communities - are at the heart of every decision we make.

Teva's Corporate Governance policies are important where it provides the company with a comprehensive structure of best practices and highest standards. We maintain compliance with these policies, ensuring the company acts responsibly, ethically and lawfully. Key to this is the great emphasis we place on transparency throughout our business - from production and development to the way we manage our business.

On the other hand Teva Turkey is one of the countries included under the International Markets which is Teva's largest geographical region, and has a strategic importance. In 2007, Teva acquired Med-İlaç Pharmaceuticals, a Turkish company, and began its operations in Turkey. In 2016, Teva changed its trademark to "Teva Turkey" and since then, it has been offering equivalent and innovative products produced in world standards for the use of Turkish medicine.

Teva Turkey, focuses on disease areas such as Central Nervous System (CNS) and Multiple Sclerosis (MS), Oncology and OTC where its Teva brand is uniquely positioned and globally recognized. It is working toward a single, common goal every day, through its original and equivalent treatments in all of these treatment areas: to improve health!

Our leadership has been shaped by our culture and our employees who have believed in us since our humble beginnings and for more than 120 years our leadership has stood out for its perseverance, entrepreneurial spirit and passion to improve people's lives. We are excited to continue helping improve the health of our Teva patients for many generations to come.

Contact Person

Name Surname: Melek Çıkar

Position: Corporate Communications Manager

Phone: +90 216 656 67 00

E-mail: melek.cikar@teva.com.tr

Company Name:
TRPHARM Pharmaceuticals
Company Web:
www.trpharm.com

Conducting its activities with the vision of becoming a global and innovative healthcare company, TRPharm plays a leading role in Turkey & MENA and the neighboring regions thanks to its unique business model and emphasis on intellectual capital. Aiming at making its presence felt in every field with unmet healthcare needs, TRPharm focuses on enabling innovative healthcare solutions for the patients. It does so by leveraging its extensive experience at every stage, from development to commercialization, with extraordinary results. TRPharm has an extensive product portfolio in oncology/hematology, neurology, immunology and rare diseases.

Contact Person

Name: Levent Soyluoğlu
Position: Finance& Strategic Planning Director
Phone: +90 212 386 31 30
E-mail: levent.soyluoglu@trpharm.com

Name: Mehtap Aydoğan
Position: Product Manager
Phone: +90 212 386 31 30
E-mail: mehtap.aydogan@trpharm.com

Company Name:
Turgut Pharmaceuticals
Company Web:
www.turgutilac.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

The main objective of Turgut Pharmaceuticals is to develop, manufacture and market high-quality biotechnological products for Turkish and global markets with the international standards-compliant biotechnology infrastructure that has been created based on R&D in Turkey.

Establishing the Biotechnology Group in early 2014 as part of a strategic decision, Turgut Pharmaceuticals redefined its priorities and main objectives, and concentrated its operations and investments in the field of biotechnology. In this framework, the company determined basic requirements for developing and manufacturing world-class biosimilar drugs by initially collaborating with domestic and international expert organizations and came up with a strategic plan based on tangible data that incorporates solutions to establish a sustainable biotechnology infrastructure as quickly as possible taking into account the conditions prevalent in our country and to develop and launch high-quality biosimilar monoclonal antibodies, and put the plan into effect. The strategic plan covers three main fields of activity, as well as the establishment of a world-class biotechnology platform in Turkey:

1. R&D-Based Product Development

In 2015, Turgut Pharmaceuticals Biotechnology Development Center, whose management and ownership belong entirely to Turgut Pharmaceuticals, was established and operationalized in the Acibadem Mehmet Ali Aydinlar University Campus. A biotechnology platform was established at this Center in order to develop world-standard biotechnology products based on R&D. At the beginning of 2020, Turgut Pharmaceuticals has moved its R&D and production activities to the Turgut Gebze Biopharmaceutical Manufacturing Site.

Now, Turgut Pharmaceuticals Biotechnology Center has become Turkey's first biotechnology R&D Center established in the field of recombinant monoclonal antibody technology equipped with the state-of-the-art technological infrastructure and qualified human resource capable of performing antibody manufacturing, as well as all comparative protein analyses with the reference product as required by EMA and FDA guidelines.

2. GMP Biotechnology Manufacturing Facility

A GMP biotechnology manufacturing facility was designed in compliance with the criteria established by EMA, Turkish Ministry of Health, and FDA in Gebze Organized Industrial Zone (GOSB) and the Turgut Gebze Biopharmaceutical Manufacturing Site became operational with the installation of all necessary technical equipment and production lines at the beginning of 2020.

The high-tech infrastructure of process development, analysis and filling lines has been established to cover the biosimilar production processes from cell line to finished product and continues its activities at the Turgut Gebze Biopharmaceutical Manufacturing Site, which received GMP Production Site Permit, GMP Biosimilar mAb Production Certificate, GMP Vaccine Certificate and TSE Covid-19 Safe Production Center Certificate in the first quarter of 2021.

3. Domestic and International Collaborations

Turgut Pharmaceuticals established collaborations with domestic and international expert organizations in the fields of training, technology, and consultancy in order to develop and manufacture high-quality biotechnology products.

In addition to its biotechnological activities, Turgut Pharmaceuticals aims to produce, market and export world-class domestic and national biosimilars and generic products in the main therapeutic markets it focuses on with the import of high value-added small molecules.

Contact Person

Name Surname: Deniz Demirhan
Position: Biotechnology Group Manager
Phone: +90 850 749 98 00
E-mail: dbaycin@turgutilac.com.tr

Name Surname: Ayfer Gültekin
Position: Deputy General Manager
Phone: +90 850 749 98 00
E-mail: agultekin@turgutilac.com.tr

Turkish Biopharmaceuticals and Vaccines Platform

Company Name:
Vem Pharmaceuticals
Company Web:
www.vemilac.com

VEM Pharmaceuticals, which has been active in healthcare industry since 2000, offers many medicinal products in the areas of Nephrology, Pulmonary Diseases, Gastroenterology, Pediatry, Urology, Dermatology, Cardiology and Cardiovasular Surgery, Intensive Care, Anesthesia to service of Turkish Medicine.

VEM Pharmaceuticals is a national company, which is conscious that Turkey must be strong in drug industry and with this awareness it started investmening to set up its own manufacturing facility in 2011. Vem Pharmaceuticals owns a factory in Cerkezkoy Industrial Zone with a 22.500 m2 closed area and continues to work both for domestic market and for export robustly.

With a GMP certificate from Turkish Ministry of Health, VEM Pharmaceuticals' biotechnological production facility is operational since 2018 and ready for product development from mammalian cell lines (CHO). VEM Pharmaceuticals' have currently 3 local biotechnological products under registration as well as planned product developments in areas such as cancer, nephrology etc. The pipeline of biosimilar products will be expanded in the near future with the collaboration of multinational biotech companies.

Contact Person
Name: Ayşe GÖKLÜ ŞENOL
Position: Regulatory Affairs and Business Development Manager
Phone: +90 312 427 43 57
E-mail: ayse.goklu@vemilac.com